Spero Therapeutics (SPRO) EBIAT (2016 - 2025)
Spero Therapeutics (SPRO) has disclosed EBIAT for 10 consecutive years, with -$7.4 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, EBIAT rose 56.73% year-over-year to -$7.4 million, compared with a TTM value of -$44.0 million through Sep 2025, down 1337.17%, and an annual FY2024 reading of -$68.6 million, down 400.88% over the prior year.
- EBIAT was -$7.4 million for Q3 2025 at Spero Therapeutics, down from -$1.7 million in the prior quarter.
- Across five years, EBIAT topped out at $51.2 million in Q4 2023 and bottomed at -$32.8 million in Q1 2022.
- Average EBIAT over 5 years is -$10.8 million, with a median of -$13.9 million recorded in 2025.
- The sharpest move saw EBIAT surged 191.56% in 2022, then plummeted 433.54% in 2024.
- Year by year, EBIAT stood at -$29.2 million in 2021, then soared by 191.56% to $26.8 million in 2022, then skyrocketed by 91.2% to $51.2 million in 2023, then crashed by 140.97% to -$21.0 million in 2024, then surged by 64.71% to -$7.4 million in 2025.
- Business Quant data shows EBIAT for SPRO at -$7.4 million in Q3 2025, -$1.7 million in Q2 2025, and -$13.9 million in Q1 2025.